LAT Investigation: NIH Scientist Ties to Pharma

The latest investigative report focusing on financial conflicts of interest by Pulitzer Prize winner, David Willman of the Los Angeles Times, reveals that even as the NIH director, Dr. Elias Zerhouni, announced publicly last year that scientists at the National Institutes of Health would be barred from accepting consulting fees from industry, evidence shows that the ban is clearly not being enforced.

Humbling Reality–Treatments for Depression Often Fail_Boston Globe

The Boston Globe reports (below): “More than 50 years after psychiatrists began widely dispensing drugs to treat mental illness, the profession is coming face to face with a humbling reality: Its treatments often fail, leaving millions of patients [  ] to suffer while doctors search for something that works.”

Study found: older patients risk death on BOTH old and new Antipsychotics

Study found: older patients risk death on BOTH old and new Antipsychotics Thu, 01 Dec 2005 Elderly patients prescribed antipsychotics–old neuroleptics (such as Haldol) or the new antipsychotics (such as Zyprexa or Risperdal)–were at increased risk of death. The risk for the older drugs is estimated to be 17.9%  and…